Maurizio Martelli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia	BLOOD	2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma	BLOOD ADVANCES	2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment	BLOOD ADVANCES	2021
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA	BLOOD ADVANCES	2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia	EXPERT OPINION ON INVESTIGATIONAL DRUGS	2021
Measuring prognosis in chronic myeloid leukemia: what's new?	EXPERT REVIEW OF HEMATOLOGY	2021
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2021
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2021
Measuring prognosis in chronic myeloid leukemia: what's new?	EXPERT REVIEW OF HEMATOLOGY	2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols	ACTA ONCOLOGICA	2021
Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study	IN VIVO	2020
Effect of low or high doses of low‐molecular‐weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID‐19	BRITISH JOURNAL OF HAEMATOLOGY	2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma	HEMATOLOGICAL ONCOLOGY	2020
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study	THE LANCET. HAEMATOLOGY	2020
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA	JOURNAL OF HEMATOLOGY & ONCOLOGY	2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA	BLOOD ADVANCES	2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience	ANNALS OF HEMATOLOGY	2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	EXPERT REVIEW OF HEMATOLOGY	2020
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab	ANNALS OF HEMATOLOGY	2020